StrokeJoSMMARTNCT07298668
Cardiovascular Risk Factors in Middle Eastern Patients With Stroke
An observational study of Stroke and Low-Density-Lipoprotein-cholesterol Level, run by Jordan Collaborating Cardiology Group at 1 site in Jordan.
Trial summary
Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke, Low-Density-Lipoprotein-cholesterol Level, Risk Factors
- How many people
- 2,000 participants
- Where
- 1 siteJordan
- Study dates
- 31 Dec 2025to 31 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Will enroll adults admitted to the hospital with a working diagnosis of stroke and then the diagnosis is confirmed by a neurologist. Patients ii be interviewed for data collection of 4 risk factors as above in addition to the serum level of LDLC and the use of lipid lowering agents.
Who may be able to join
- Diagnosis of stroke upon admission to the hospital
- Adult aged 18 years or older
- Available lipid profile on hospital admission
Who cannot join
- Stroke diagnosis unconfirmed
- age younger than 18 years
- No available lipid profile on admission
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Jordan1 site
Istishari Hospital
Amman, 11184
Laith Habahbeh, MD, 065001000, hammoudeh_ayman@yahoo.com
Ayman Hammoudeh, MD, FACC, FSCAI, 065001000, hammoudeh_ayman@yahoo.com
About this study
Official title: Standard Modifiable Risk Factors in Middle Eastern Patients With Stroke (Jo-SMMART Study)
Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.
Read the detailed description
Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.
These clinically relevant issues have not been studied extensively in the Middle East where most of the studies in atherosclerotic cardiovascular disease have focused on acute coronary syndrome more than stroke. Exploring new information on risk factors of stroke in this region that helps fill some of the knowledge gaps.
Stroke has been attributed, in the majority of cases, to the traditional four standard modifiable risk factors of hypertension, type 2 diabetes, dyslipidemia, and cigarette smoking. However, ethnicity and geography account for the interregional differences of the prevalence of risk factors in patients with stroke.
The Jo-SMMART ill evaluate risk factors in 2000 stroke patients in Jordan as a representative of the Middle Eastern population, the prevalence of those with none of the 4 risk factors and the differences in clinical profiles and demographic features on those with risk factors and those with no risk factors. Lipid profile and use of lipid lowering agents will also be evaluated, and furthermore the die0fferneces between young vs old, and men vs women stroke patients ill be addressed.
- Keywords
- Stroke, Risk factors
- Medical subject headings
- Stroke
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of hypertension in stroke patients (survey interview)
BP more 140/90 or known diagnosis of high blood pressure or patient already on blood pressure medication
Measured: Baseline
Prevalence of type 2 diabetes in stroke patients (survey interview)
HbA1c more than 6.5%, or known diagnosis of type 2 diabetes or patient already on anti diabetes medications
Measured: BASELINE
Prevalence of elevated serum level of low density lipoprotein cholesterol in stroke patients (survey interview)
Elevated serum level of low density lipoprotein cholesterol > 55 mg/dl or patient already on lipid lowering medication
Measured: BASELINE
Prevalence of current cigarette smoking in stroke patients (survey interview)
Known current cigarette smoking of any number of cigarettes per day
Measured: BASELINE
Use of lipid lowering therapy (survey interview)
Current use of statin, ezitimibe, PCS9 inhibitor of small interfering RNA agent to lower the LDL-C
Measured: BASELINE
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2025
- Study start31 Dec 2025 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jordan Collaborating Cardiology Group
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07298668
- Sponsor's protocol ID
- JOCVA1.NOV2025/2
- Acronym
- JoSMMART
- Status last verified
- Dec 2025
- First submitted
- 26 Nov 2025
- Last updated
- 23 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All individual participant data will be available in the form of excel sheet with no disclosure of patients names. Can be requested from the study director
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Standard Modifiable Risk Factors in Middle Eastern Patients With Stroke (Jo-SMMART Study)
- ClinicalTrials.gov ID
- NCT07298668
- Acronym / sponsor ID
- JoSMMART / JOCVA1.NOV2025/2
- Keywords
- Stroke, Risk factors
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Jordan Collaborating Cardiology GroupUniversity, hospital or other
- Study start
- 31 Dec 2025 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Jan 2027 (estimated)
- First posted
- 23 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.
Detailed description
Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.
These clinically relevant issues have not been studied extensively in the Middle East where most of the studies in atherosclerotic cardiovascular disease have focused on acute coronary syndrome more than stroke. Exploring new information on risk factors of stroke in this region that helps fill some of the knowledge gaps.
Stroke has been attributed, in the majority of cases, to the traditional four standard modifiable risk factors of hypertension, type 2 diabetes, dyslipidemia, and cigarette smoking. However, ethnicity and geography account for the interregional differences of the prevalence of risk factors in patients with stroke.
The Jo-SMMART ill evaluate risk factors in 2000 stroke patients in Jordan as a representative of the Middle Eastern population, the prevalence of those with none of the 4 risk factors and the differences in clinical profiles and demographic features on those with risk factors and those with no risk factors. Lipid profile and use of lipid lowering agents will also be evaluated, and furthermore the die0fferneces between young vs old, and men vs women stroke patients ill be addressed.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Will enroll adults admitted to the hospital with a working diagnosis of stroke and then the diagnosis is confirmed by a neurologist. Patients ii be interviewed for data collection of 4 risk factors as above in addition to the serum level of LDLC and the use of lipid lowering agents.
Key inclusion criteria (3 listed)
- Diagnosis of stroke upon admission to the hospital
- Adult aged 18 years or older
- Available lipid profile on hospital admission
Key exclusion criteria (3 listed)
- Stroke diagnosis unconfirmed
- age younger than 18 years
- No available lipid profile on admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of hypertension in stroke patients (survey interview)
Time frame: Baseline
BP more 140/90 or known diagnosis of high blood pressure or patient already on blood pressure medication
Prevalence of type 2 diabetes in stroke patients (survey interview)
Time frame: BASELINE
HbA1c more than 6.5%, or known diagnosis of type 2 diabetes or patient already on anti diabetes medications
Prevalence of elevated serum level of low density lipoprotein cholesterol in stroke patients (survey interview)
Time frame: BASELINE
Elevated serum level of low density lipoprotein cholesterol > 55 mg/dl or patient already on lipid lowering medication
Prevalence of current cigarette smoking in stroke patients (survey interview)
Time frame: BASELINE
Known current cigarette smoking of any number of cigarettes per day
Use of lipid lowering therapy (survey interview)
Time frame: BASELINE
Current use of statin, ezitimibe, PCS9 inhibitor of small interfering RNA agent to lower the LDL-C
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2025.
- Individual participant dataSharing planned: Yes. All individual participant data will be available in the form of excel sheet with no disclosure of patients names. Can be requested from the study director
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke and Low-Density-Lipoprotein-cholesterol Level, run by Jordan Collaborating Cardiology Group at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laith Habahbeh, MD (065001000, a.hammoudeh@istisharihospital.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of hypertension in stroke patients (survey interview) (time frame: Baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.